MedTrace Logo

Dopamine in Acute Decompensated Heart Failure II

NCT01060293 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2013-09-11

No results posted yet for this study

Summary

The aim of this study is to compare the effects of 1) high-dose furosemide, 2) low-dose furosemide, and 3) low-dose furosemide combined with low-dose dopamine on diuresis, clinical status, renal function, electrolyte balance, length of stay, and 60-day post-discharge outcomes in patients hospitalized with acute decompensated heart failure.

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

High-dose furosemide

High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours

DRUG

Low-dose furosemide

Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide

DRUG

Low-dose furosemide combined with low-dose dopamine

Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours

Sponsors & Collaborators

  • Larissa University Hospital

    lead OTHER

Principal Investigators

  • Gregory Giamouzis, MD · Department of Cardiology, Larissa University Hospital, Larissa, Greece

  • Filippos Triposkiadis, MD · Department of Cardiology, Larissa University Hospital, Larissa, Greece

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States
  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01060293 on ClinicalTrials.gov